The absence of pRB expression renders human breast cancer cells more sensitive to 5-FU and methotrexate and predicts a good clinical outcome for patients treated with adjuvant chemotherapy. We suggest that patients with RB-negative breast cancers should be treated with systemic chemotherapy.
No takes yet. Share an insight, caveat, or question.
Derenzini et al. (2008) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: